Preliminary clinical experiences with the use of immunomodulators in burns.
The remarkable progress achieved in control of infections in burned patients has significantly increased survival rates. Nevertheless, septic complications are still the leading cause of death in these patients. The immunologic disturbances present after severe burns certainly play a key role in susceptibility to infection, and in particular the impairments of the phagocytic system warrant major investigative efforts in order to increase host defenses. Determination of phagocytic and microbicidal capacity of neutrophils from burned patients evidenced a marked functional impairment of these cells. The alterations recorded were partly due to intrinsic (cellular) defects, and partly to extrinsic (serum) defects. Indeed, opsonic factors are known to be reduced in these patients, but also phagocytosis-inhibiting factors such as immunocomplexes have been detected in the patients we have studied. Administration of the immunomodulating agents methysoprinol and timostimoline were found to be effective in partially restoring neutrophil function. Rational immunotherapy in burned patients will consist of replacement of humoral mediators, clearance of inhibitory factors and stimulation of the cellular effectors of immunity.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control; D002056:Burns / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D005353:Fibronectins / Q000097:blood; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000494:pharmacology / Q000627:therapeutic use*; D008214:Lymphocytes / Q000276:immunology; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D010587:Phagocytosis / Q000187:drug effects; D013949:Thymus Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D000276:Adjuvants, Immunologic; D005353:Fibronectins; D013949:Thymus Extracts; C031407:thymostimulin; D007288:Inosine; D007542:Inosine Pranobex